Techniclone Expands Cotara Clinical Study to Include the University of Miami; Company to Expand Brain Cancer Trial
TUSTIN, Calif.--(BUSINESS WIRE)--June 1, 2000--Techniclone Corporation (NASDAQ:TCLN), today announced that the Phase II clinical study for the treatment of brain cancer has been expanded to include the University of Miami.
Techniclone will commence the evaluation, enrollment and treatment of patients at the University of Miami as part of its planned expansion of the Phase II clinical trial. The Company plans to continue to add additional sites in order to increase enrollment for the Cotara(TM) brain trial. The University of Miami joins the Medical University of South Carolina, the University of Utah, Temple University and Carolina Neurosurgery and Spine Associates as an active site in this ongoing clinical trial.
Dr. Terrence Chew, Vice President of Clinical and Regulatory Affairs, commented, "The completion of the Phase II Cotara(TM) clinical study remains paramount in Techniclone's efforts to realize commercialization of its most advanced platform technology." Dr. Aldo Serafini Professor of Radiology and Professor of Medicine at the University of Miami School of Medicine will act as lead investigator. "With approximately 15,000 diagnosed cases of glioma in the U.S, the Company believes that increasing the number of sites will both increase the enrollment rate for this trial and will put Cotara(TM) into the hands of more physicians capable of providing valuable feedback on the performance and characteristics of the drug," concluded Dr. Chew.
"Our plan is to move Cotara(TM) clinical studies along as rapidly as possible. The increase in sites for this study is part of our overall commitment to expand clinical trials for Cotara(TM) for the brain and eventually for other solid tumor indications as well." stated Dr. John Bonfiglio, President and CEO of Techniclone. The expansion of the brain trial demonstrates Techniclone's strategy to focus on clinical trial results and to obtain these results in the most cost efficient and expeditious manner possible." concluded Dr. Bonfiglio.
Techniclone Corporation is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies". These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attach solid tumors, without causing damage to surrounding healthy tissue. The Company has three collateral targeting technologies: Cotara(TM), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents, (VTA). The Company also has a direct tumor targeting agent called Oncolym(R) for the treatment of advanced non-Hodgkin's B-cell Lymphoma. Oncolym(R) has been licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym(R) clinical trial programs as well as marketing.
Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the Company's expectations as a result of risk factors discussed in Techniclone's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's report on Form 10K for the year ended April 30, 1999 and Form 10Q for the quarter ended January 31,2000.
CONTACT: DeMonte Associates, New York
Cynthia DeMonte
800/987-8256 or 212/420-0088
Copyright 2000, Business Wire. All of the releases provided by Business Wire are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who are solely responsible for their content, accuracy and originality. All reproduction, other than for an individual user's reference, is prohibited without prior written permission.
Home | About Us | Feedback | Investor Resources | Index-Based Investments
Help & Reference | Site Map & Site Tour | Site Search
© Copyright 2000, The Nasdaq Stock Market, Inc. All Rights Reserved.
Please read our Disclaimer, Trademarks, and Privacy Statement.
TUSTIN, Calif.--(BUSINESS WIRE)--June 1, 2000--Techniclone Corporation (NASDAQ:TCLN), today announced that the Phase II clinical study for the treatment of brain cancer has been expanded to include the University of Miami.
Techniclone will commence the evaluation, enrollment and treatment of patients at the University of Miami as part of its planned expansion of the Phase II clinical trial. The Company plans to continue to add additional sites in order to increase enrollment for the Cotara(TM) brain trial. The University of Miami joins the Medical University of South Carolina, the University of Utah, Temple University and Carolina Neurosurgery and Spine Associates as an active site in this ongoing clinical trial.
Dr. Terrence Chew, Vice President of Clinical and Regulatory Affairs, commented, "The completion of the Phase II Cotara(TM) clinical study remains paramount in Techniclone's efforts to realize commercialization of its most advanced platform technology." Dr. Aldo Serafini Professor of Radiology and Professor of Medicine at the University of Miami School of Medicine will act as lead investigator. "With approximately 15,000 diagnosed cases of glioma in the U.S, the Company believes that increasing the number of sites will both increase the enrollment rate for this trial and will put Cotara(TM) into the hands of more physicians capable of providing valuable feedback on the performance and characteristics of the drug," concluded Dr. Chew.
"Our plan is to move Cotara(TM) clinical studies along as rapidly as possible. The increase in sites for this study is part of our overall commitment to expand clinical trials for Cotara(TM) for the brain and eventually for other solid tumor indications as well." stated Dr. John Bonfiglio, President and CEO of Techniclone. The expansion of the brain trial demonstrates Techniclone's strategy to focus on clinical trial results and to obtain these results in the most cost efficient and expeditious manner possible." concluded Dr. Bonfiglio.
Techniclone Corporation is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies". These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attach solid tumors, without causing damage to surrounding healthy tissue. The Company has three collateral targeting technologies: Cotara(TM), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents, (VTA). The Company also has a direct tumor targeting agent called Oncolym(R) for the treatment of advanced non-Hodgkin's B-cell Lymphoma. Oncolym(R) has been licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym(R) clinical trial programs as well as marketing.
Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the Company's expectations as a result of risk factors discussed in Techniclone's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's report on Form 10K for the year ended April 30, 1999 and Form 10Q for the quarter ended January 31,2000.
CONTACT: DeMonte Associates, New York
Cynthia DeMonte
800/987-8256 or 212/420-0088
Copyright 2000, Business Wire. All of the releases provided by Business Wire are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who are solely responsible for their content, accuracy and originality. All reproduction, other than for an individual user's reference, is prohibited without prior written permission.
Home | About Us | Feedback | Investor Resources | Index-Based Investments
Help & Reference | Site Map & Site Tour | Site Search
© Copyright 2000, The Nasdaq Stock Market, Inc. All Rights Reserved.
Please read our Disclaimer, Trademarks, and Privacy Statement.
